A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy followed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temozolomide monotherapie in patients with newly diagnosed glioblastoma and a non-methylated MGMT-promoter (GLARIUS)

Trial Profile

A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy followed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temozolomide monotherapie in patients with newly diagnosed glioblastoma and a non-methylated MGMT-promoter (GLARIUS)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms GLARIUS
  • Sponsors Roche
  • Most Recent Events

    • 14 Mar 2016 Results published in the Journal of Clinical Oncology
    • 13 Oct 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 03 Jun 2014 Secondary endpoints presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top